Physician profile
Leonard M Bley
NPI 1578541991
$19,380.69
in general payments reported to CMS, 2019-2025
32 companies · $2,033 in 2025
The $2,033 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,143 · 2020: $4,137 · 2021: $1,630 · 2022: $1,074 · 2023: $1,800 · 2024: $5,564 · 2025: $2,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,397 · Debt Forgiveness: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,396.68 |
| Debt Forgiveness | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $7,136.72 | 2019-2025 | Argos, Clareon, Centurion |
| Convatec INC. | $3,000.00 | 2024 | |
| Bausch & Lomb Americas INC. | $1,442.68 | 2023-2025 | Envista Mx60 Iol, Xiidra, Toric |
| Allergan, INC. | $922.37 | 2019-2022 | |
| Sight Sciences, INC. | $714.35 | 2019-2024 | Omni Surgical System |
| Abbvie INC. | $680.13 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Sun Pharmaceutical Industries INC. | $668.25 | 2019-2025 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $659.61 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Catalys System |
| Kala Pharmaceuticals, INC. | $500.26 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $456.26 | 2020-2025 | Acthar |
| Carl Zeiss Meditec, INC. | $454.05 | 2019-2020 | |
| Glaukos Corporation | $436.72 | 2020-2024 | Idose |
| Biotissue Holdings INC. | $392.14 | 2022-2024 | |
| New World Medical,INC. | $265.72 | 2019-2025 | Ahmed Glaucoma Valve, Streamline, Via360 |
| Tarsus Pharmaceuticals, INC. | $258.75 | 2024-2025 | Xdemvy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $239.94 | 2019-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $179.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $150.43 | 2019-2022 | |
| Oyster Point Pharma, INC. | $147.94 | 2022-2023 | Tyrvaya |
| Omeros Corporation | $118.37 | 2019 | |
| Eyepoint US, INC. | $107.14 | 2020 | |
| Rxsight INC | $78.13 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $78.05 | 2019-2021 | |
| Ocular Therapeutix, INC. | $54.71 | 2019-2024 | Dextenza |
| Shire North American Group INC | $45.81 | 2019 | |
| Horizon Therapeutics Plc | $43.66 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $43.18 | 2024 | Artevo 800 |
| Akorn Operating Company LLC | $25.05 | 2021 | |
| Halozyme INC | $23.48 | 2024 | Hylenex Recombinant |
| Akorn, INC. | $20.55 | 2020 | |
| Amgen INC. | $19.09 | 2025 | Tepezza |
| Harrow Eye, LLC | $17.21 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Bley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.